Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Alumis is currently a financially risky investment as there is potential for the market for envu to be smaller than expected due to competition from other therapies and challenges in penetrating the market. Additionally, Alumis may face financing risks as it continues to expand R&D and commercialization efforts before becoming profitable. However, with a reported net loss of $93.1MM and a strong balance sheet with $569.5MM in cash, Alumis is positioned to potentially overcome these challenges and achieve a valuation of $3.8B, driven by envu's potential in PsO and SLE. Risks to keep in mind include delays in regulatory approvals, competition in the I&I space, and potential equity dilution.

Bears say

Alumis is currently in the clinical stage of development, and despite their promising phase II and phase III data for their candidates in some indications, there is still the possibility for pivotal trials in others to not meet efficacy endpoints due to variability in patients or disease trajectories. Additionally, with a crowded market and established competitors in the biopharmaceutical industry, Alumis's current pipeline may struggle to achieve a competitive benefit/risk profile in the long-term. Given these concerns, the financial analyst maintains a Neutral rating on the stock and has set a 12-month price target of $25.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Jul 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.